DARS2 Promotes Tumorigenesis and Metastasis by Activating PI3K / Akt / GSK ‐3β/β‐Catenin Signaling Pathway in Breast Cancer
The Kaohsiung Journal of Medical Sciences · 07.08.2026
DOI: 10.1002/kjm2.70267 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 07.08.2026. Verfasst von Na Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aspartyl‐tRNA synthetase 2 (DARS2), the mitochondrial enzyme responsible for aminoacylation of aspartyl‐tRNA, is traditionally known for its effect on protein synthesis. Recently, DARS2 is reported to be implicated in tumorigenesis. However, its specific effect on breast cancer (BC) is poorly understood. The present work employed bioinformatics tools for analyzing DARS2 expression among BC patients and its association with clinicopathological characteristics and patient prognosis. We evaluated DARS2 expression within BC cells and tissues and assessed how DARS2 knockdown or PI3K pathway activation affected cell growth, migration, invasion, apoptosis, as well as cell cycle progression. Mechanistically, we analyzed how DARS2 regulated the PI3K/Akt/GSK‐3β/β‐catenin pathway. Additionally, a xenograft tumor model was constructed to validate our in vitro findings. According to our observations, DARS2 expression significantly increased in BC cells and tissues. Knockdown of DARS2 markedly suppressed cell growth, invasion, migration, and epithelial‐mesenchymal transition (EMT), but enhanced their apoptosis. Mechanistic studies revealed that DARS2 knockdown suppressed the PI3K/Akt/GSK‐3β/β‐catenin pathway, whereas PI3K pathway activation with 740Y‐P reversed the impacts of DARS2 knockdown. In vivo experimental results further verified that DARS2 suppression significantly suppressed tumor growth and metastasis through downregulating the PI3K/Akt/GSK‐3β/β‐catenin pathway. Collectively, these results indicate that DARS2 promotes the growth, migration, invasion, and EMT of BC cells by regulating the PI3K/Akt/GSK‐3β/β‐catenin signaling pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China.
- Department of Thyroid and Breast Surgery, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, The Clinical Research Center for Acute Myocardial Infarction of Hubei Pro…
ORCID-Profile: Ming Huang
Zitieren
APA
Wang, N., & Huang, M. (2026). DARS2 Promotes Tumorigenesis and Metastasis by Activating PI3K / Akt / GSK ‐3β/β‐Catenin Signaling Pathway in Breast Cancer. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70267
Vancouver
Wang N, Huang M. DARS2 Promotes Tumorigenesis and Metastasis by Activating PI3K / Akt / GSK ‐3β/β‐Catenin Signaling Pathway in Breast Cancer. The Kaohsiung Journal of Medical Sciences. 2026. doi:10.1002/kjm2.70267
BibTeX
@article{Wang2026,
author = {Wang, Na and Huang, Ming},
title = {DARS2 Promotes Tumorigenesis and Metastasis by Activating PI3K / Akt / GSK ‐3β/β‐Catenin Signaling Pathway in Breast Cancer},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2026},
doi = {10.1002/kjm2.70267}
}
EUVIMED